The Discounted Cash Flow (DCF) valuation of Erytech Pharma SA (ERYP.PA) is (7.51) EUR. With the latest stock price at 0.50 EUR, the upside of Erytech Pharma SA based on DCF is -1604.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.2% - 7.3% | 6.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (71.21) - (3.78) | (7.51) |
| Upside | -14370.0% - -857.1% | -1604.9% |